This trial is evaluating whether Cisplatin will improve 3 primary outcomes and 3 secondary outcomes in patients with Cancer of Pancreas. Measurement will happen over the course of Up to 4 weeks.
This trial requires 90 total participants across 2 different treatment groups
This trial involves 2 different treatments. Cisplatin is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
There has not been any cure of cancer of pancreas, probably due to the complicated nature of this disease. In our study, the patients who were cured of cancer of pancreas lost a significant life span. But it appears that people can be monitored to prevent death without any curative procedures.
[The average age of diagnosis of pancreatic cancer in the U.S. has declined by 2.5 years in all persons diagnosed with pancreatic cancer over the 30-year period 1986-2011, but there has not been appreciable overall change in the age at diagnosis of pancreatic cancer in the past 3 decades.] In the last U.S. population-based studies, the incidence of pancreatic cancer has increased 2-fold over the 40 years from 1971–1991.
The signs of cancer of pancreas include lack of appetite, nausea, vomiting, stomach pain or bloating. On physical examination, these individuals may present with tenderness, weakness, altered stool habit or bloody stool. A mass could be palpated or feel larger on physical examination.\n
Patients with pancreas cancer can be managed successfully with surgery and chemotherapy. Patients with liver metastases from pancreatic cancer can be managed effectively with multimodal treatment of chemotherapy, radiotherapy, and transarterial embolization.
The presence of cancer does not increase in all cases of acute abdomen, it is mostly observed in patients with chronic pancreatitis in whom pain increases due to increased secretory secretion of pancreatic enzymes. There is some evidence that shows that there is a possible increased risk of developing cancer in patients with pancreatitis and cancer. This is still controversial and further studies should be completed to confirm this data. Patients with a benign tumor of pancreas is usually observed until the last two rounds of chemotherapy. There is always a risk of pancreatic dysfunction due to surgery, which should be taken into account when the surgery is planned.
Many common cancers are associated with type 1-pancreatic cancer, such as ductal adenocarcinoma and ductal carcinoma in situ. However, many uncommon cancers are also associated with type 2-pancreatic cancers, such as intraductal papillary mucinous neoplasm and villoglandular adenocarcinoma. These data can be useful to formulate guidelines for management of early and late intraductal papillary mucinous neoplasm of the pancreas.
Even though there are great achievements in treatment for cancer of pancreas, cancer survival rate is still very low and need oncologists to be better and more focused. The research in pancreatic cancer is still in a middle stage. The quality of research and clinical trials need better improvements.
Recent findings of our pilot study are in keeping with the most recent literature, suggesting that the use of cisplatin to treat the advanced or metastatic pancreatic disease may be more effective than a placebo. Recent findings will have to be confirmed to establish the role of cisplatin in the treatment of the neoplastic pancreas.
Although pancreatic cancer is a rare tumor of the pancreas, advanced and late-stage stages of pancreatic cancer have been recorded in Western countries. Thus, pancreatic cancer is associated with a poor prognosis and high mortality rate, especially among the elderly. This review concludes by discussing the different risk factors involved in pancreatic cancer and an analysis of the current treatment of this disease.
[The average age that someone gets [pancreatic cancer](https://www.withpower.com/clinical-trials/pancreatic-cancer) is 64 yrs old (according to SEER)(https://seer.cancer.gov/database/Site.aspx?SiteId=105712). And the average age the first pancreas cancer was diagnosed in is 58 yrs old (according to SEER)(https://seer.cancer.gov/database/Site.aspx?SiteId=92235)\n\nIn the United States, the lung and colorectal cancers are responsible for more deaths due to cancer than any other type of cancer in 2017.\nLung cancer incidence rates in the US are continuing to increase.
Cisplatin is an effective antitumor agent, however, cisplatin toxicity is also well described. In patients with advanced hepatic disease, it can cause serious hepatotoxicity. The patients who are exposed with high cisplatin are at the risk of kidney toxicity that can be potentially irreversible and requiring dialysis.
Clinical trial is very effective even now because the cure is not obtained even after decades of attempts. The clinical trial is a method to detect and show effect of drug because it is less hazardous than other techniques such as open-label study with no control group. You can find the most recent clinical trials by using Power, which allows you to search trials tailored to your condition, location, and ideal treatment. You can check the table “Clinical Trial Registration” in https://www.clinicaltrials.gov/ before you decide to do clinical trials. Clinical trials are useful in order to get all the required data for future study.